Future Trends in Oncology: Insights from Expert Roundups
Precision Oncology and Genetic Testing
The realm of oncology is rapidly evolving, with precision medicine at the forefront of this transformation. Marwan G. Fakih, MD, of City of Hope, highlights the critical role of genetic testing, particularly for patients with KRAS G12C mutations in metastatic colorectal cancer (mCRC). These mutations, found in approximately 4% of mCRC patients, necessitate next-generation sequencing at diagnosis to guide treatment decisions and improve outcomes.
madness,tha<
Early Identification and Precision Strategies
Fakih emphasizes the need for early identification of targetable mutations and the integration of precision oncology strategies. The combination of sotorasib (Lumakras) and panitumumab (Vectibix) has shown promising results, leading to its approval as a doublet regimen by the FDA. The efficacy of this combination, coupled with its acceptable safety profile, underscores the importance of precision oncology in improving patient outcomes.
Triplet Regimens in Multiple Myeloma
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses the shift in treatment standards for multiple myeloma. Triplet regimens, such as bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd), and carfilzomib (Kyprolis), lenalidomide, and dexamethasone (KRd), have become the new norm, replacing older doublet regimens. These triplet combinations have shown significant improvements in response quality and depth, especially for high-risk patients.
Oral Treatment Options
Richardson highlights the benefit of ixazomib (Ninlaro)-based regimens, which offer an oral treatment option. This is particularly beneficial for frailer patients or those unable to frequently visit infusion centers. The addition of anti-CD38 monoclonal antibodies like isatuximab has further enhanced treatment efficacy, making triplet regimens the preferred choice for newly diagnosed myeloma patients.
Leveraging HER2 Testing in Breast Cancer
Aditya Bardia, MD, MPH, FASCO, of UCLA Health Jonsson Comprehensive Cancer Center, discusses the FDA approval of trastuzumab deruxtecan (T-DXd; Enhertu) for HER2-low and -ultralow metastatic breast cancer. This approval has significant implications for future HER2 testing strategies, as even minimal HER2 expression qualifies patients for treatment with the antibody-drug conjugate.
Future of HER2 Testing
Bardia emphasizes the importance of evaluating HER2 expression by immunohistochemistry (IHC). Ongoing trials, such as DESTINY-Breast15, are investigating the drug’s potential in patients with HER2 IHC 0 breast cancer. Future research is expected to refine HER2-targeted treatments and optimize patient outcomes.
Yes
Accessibility of Clinical Trials and Treatment
Marco Ruella, MD, of University of Pennsylvania Perelman School of Medicine, discusses the critical need for ensuring that advanced cancer treatments, including CAR T-cell therapies, are accessible to diverse patient populations. He notes that while advanced therapies are frequently showcased at conferences, their real-world benefits remain unclear if they are not accessible to all patients.
Challenges in Accessibility
Ruella highlights that treatments limited to tertiary centers may exclude many patients, stressing the need to incorporate these therapies into community practices for broader access. His team’s research presented at the 2024 ASH Annual Meeting showed that minority health populations have equitable access to tertiary care but face reduced access to commercial anti-BCMA CAR T-cell therapy.
Key Information Summary
| Expert | Topic | Key Points |
|---|---|---|
| Marwan G. Fakih, MD | Genetic Testing in KRAS G12C–Mutant mCRC | Emphasizes the importance of early genetic testing and precision oncology strategies. |
| Paul G. Richardson, MD | Triplet Regimens in Myeloma | Triplet regimens are the new standard, with oral treatment options and improved response depth. |
| Aditya Bardia, MD, MPH, FASCO | HER2 Testing in Breast Cancer | FDA approval for T-DXd in HER2-low and -ultralow metastatic breast cancer. |
| Ignacio Garrido-Laguna, MD, PhD, MBA | Safety of Daraxonrasib in KRAS G12X-PDAC | Ongoing research on the safety and efficacy of Daraxonrasib in KRAS G12X-mutated pancreatic cancer. |
| Marco Ruella, MD | Clinical Trial and Treatment Accessibility | Need for broader access to advanced therapies, including CAR T-cell therapies. |
Did you know?
Recognizing your particular circumstances might not resemble someone else’s does not relieve you of the need to comply with the relevant legal standards. While sharing my opinion based on what I read, I realize I am not trying to diagnose anyone or introduce evidence.
Practice Trends
Clinical Trial and Treatment Accessibility
Marco Ruella, MD, of the University of Pennsylvania Perelman School of Medicine and Hospital of the University of Pennsylvania, underscores the critical need to ensure that advanced cancer treatments, including CAR T-cell therapies, are accessible to diverse patient populations, particularly in multiple myeloma. Although clinical trial data may be presented at medical conferences like the ASH Annual Meeting, their benefits in real-world settings are inconsequential if not accessible to all patients.
Importance of Accessible Therapies
Despite therapies being frequently highlighted at conferences, Ruella asserts that treatments often confined to large healthcare centers may restrict many minorities. His team’s findings from the 2024 ASH Annual Meeting revealed that, while minority health populations have equitable access to tertiary care, access to commercial anti-BCMA CAR T-cell therapy is significantly reduced.
Expert Interview Insights
For more insights from these leaders in the oncology field, watch our recent OncLive TV segments and listen to expert interviews on OncLive On Air.
FAQ
What is the significance of next-generation sequencing in cancer treatment?
Next-generation sequencing allows for the early identification of targetable mutations, guiding treatment decisions and improving patient outcomes.
Why are triplet regimens preferred over doublet regimens in myeloma treatment?
Triplet regimens have shown improved response quality and depth, particularly for high-risk patients, making them the preferred choice.
What is the impact of FDA’s approval of trastuzumab deruxtecan for HER2-low breast cancer?
The approval allows for the treatment of patients with minimal HER2 expression, refining HER2-targeted therapies and optimizing patient outcomes.
How can accessibility to advanced cancer treatments be improved?
Incorporating advanced therapies into community practices and ensuring equitable access for diverse patient populations can enhance the real-world benefits of these treatments.
Which mutation (KRAS G12X) is linked to which cancer?
KRAS G12X mutations are more closely linked than KRAS G12C mutations to pancreatic ductal adenocarcinoma cancer.
Explore More
To stay updated on the latest trends and insights in oncology, explore more articles and expert interviews on our platform. Did you implement any of these new advancements recently in your practice, how do you find it?
Pro Tips
*Stay informed about the latest genetic testing and precision oncology strategies to enhance patient care.
Engage with expert interviews and medical meeting updates to gain insights into practice-changing data and regulatory updates.
Engage with our content by leaving a comment, asking a question about the topics we presented, or suggesting more themes you’d like us to cover in our next article.
